Adjusts earnings and sales forecasts for the first quarter.
BioNTech BNTX, -4.05 percent, a U.S.-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, owing primarily to its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma, as well as direct sales to customers in Germany and FactSet polled analysts, who predicted earnings of €9.70 per share on €4.59 billion in revenue. BioNTech and Pfizer invoiced roughly 750 million COVID-19 vaccination doses in the first quarter of 2022. It reaffirmed its 2022 goals, which include COVID-19 vaccine revenue of between €13 billion and €17 billion. BioNTech shares rose 2% in premarket activity, but are down 47% this year.